Hormonal changes in a man's aging body can cause the prostate to grow—resulting in urinary problems since the gland is wrapped around the urethra, as seen in this image taken from Asklepios Atlas of the Human Anatomy of the prostate sitting below the ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 patients worldwide and was led by Cedars-Sinai researchers.

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide and leuprolide,

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with PSMA+ mHSPC.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about managing side effects following prostate cancer treatment. While treatment modalities for prostate cancer may cause a variety of side ...

SpaceOAR Hydrogel is a polyethylene glycol–based hydrogel designed to create space between the prostate and rectum to reduce the radiation dose to the rectum during radiation therapy for prostate cancer. It has also been found to help reduce bowel, urinary, and sexual complications. 2

Former President Joe Biden has finished a round of radiation therapy to treat the aggressive form of prostate cancer he was diagnosed with in May. The 82-year-old has been receiving treatment at